Evidence map›Paper›PMID 25742869›Full record

ReviewThe Canadian journal of cardiology2015

Hemodynamics should be the primary approach to diagnosing, following, and managing pulmonary arterial hypertension.

Bradley A Maron

Registry-linked trialOpen access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The Canadian journal of cardiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05618093 (Use of Non-invasive Measurement of Cardiac Output and Stroke Volume to Assess Risk and Response to Treatment in Patients With PAH or CTEPH), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05618093 nawithdrawnnot on this mapstarted 2023, after this paper: background citation

Use of Non-invasive Measurement of Cardiac Output and Stroke Volume to Assess Risk and Response to Treatment in Patients With PAH or CTEPH

TypeinterventionalSponsorUniversity of California, Los AngelesRan2023 to 2024Enrolled0ConditionsPulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary HypertensionArmsNon-invasive hemodynamic measurements
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 10 citations in OpenAlex.

  1. Circulating NEDD9 is increased in pulmonary arterial hypertension: A multicenter, retrospective analysis.The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation · 2020
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Bradley A MaronBrigham and Women's Hospital and Harvard Medical School, Department of Medicine, Division of Cardiovascular Medicine, 75 Francis St, Boston, and the Department of Cardiology, Veterans Affairs Boston Healthcare System, West Roxbury, Massachusetts, USA. Electronic address: bmaron@partners.org.
Brigham and Women's Hospital · US

Funding

Targeting FAK-NEDD9 protein-protein interaction to prevent focal adhesion assembly and vascular proliferation in pulmonary arterial hypertensionR01HL139613 · NHLBI · UNIVERSITY OF MARYLAND BALTIMORE · PI Sirano Dhe-Paganon, Bradley Maron · 2018 to 2026
$4.1M
Aldosterone impairs endothelin B-dependent synthesis of nitric oxide to promote pK08HL111207 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI MARON, BRADLEY · 2013 to 2017
$754k
NHLBI NIH HHS 1K08HL111207-01A1NHLBI NIH HHS K08 HL111207NHLBI NIH HHS R01 HL139613
6 · The paper itself

Abstract

Pulmonary arterial hypertension (PAH) is a highly morbid cardiopulmonary disease characterized by plexogenic pulmonary arteriole remodelling. Importantly, PAH severity correlates inversely with cardiac output and directly with pulmonary vascular resistance and right atrial pressure, illustrating the importance of accurately measured hemodynamics to define the clinical profile of patients. Currently available noninvasive technology offers only hemodynamic estimates. In contrast, right heart catheterization is the principle diagnostic procedure in PAH and is required to: (1) definitively exclude alternative pulmonary vascular diseases; and (2) quantify hemodynamics at baseline, after vasoreactivity testing, or in response to therapy to prognosticate outcome and guide therapeutic escalation.

Indexed as

Disease ManagementHypertension, PulmonaryDiagnostic ImagingHemodynamicsHumans

Identifiers

PMID25742869
PMCPMC4377110
OpenAlexW2131248283

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.